Addex Therapeutics (CH:ADXN)
:ADXN
Want to see CH:ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
CHF0.04
<CHF0.01(4.65%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.03 - CHF0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)206.07K
Market Cap
CHF5.40M
Enterprise ValueCHF5.38M
Total Cash (Recent Filing)CHF1.64M
Total Debt (Recent Filing)CHF34.69K
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Jun 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding218,654,500
10 Day Avg. Volume188,431
30 Day Avg. Volume206,072
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GPCR Allosteric Modulator PlatformAddex’s core scientific focus on GPCRs and allosteric modulators is a durable strategic asset: this mechanism offers differentiated pharmacology and long development pipelines across multiple CNS indications, supporting repeated program opportunities and long-term R&D optionality.
Collaboration/licensing Revenue ModelA partnership-driven business model creates durable non-dilutive funding routes via upfronts, R&D reimbursements, milestones, and potential royalties; this structure lets a clinical-stage biotech advance programs without needing immediate product sales, preserving runway if partners engage.
Low Financial LeverageVery low debt reduces fixed financial obligations and bankruptcy risk, providing flexibility to raise capital through equity or partner deals and sustaining operations during extended development cycles typical for biotechs without the pressure of servicing significant borrowings.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company cannot self-fund development and must repeatedly access external capital or partner funding; over 2–6 months this structural cash burn elevates financing risk and potential dilution for shareholders.
Small, Volatile Revenue And Inconsistent ProfitabilityVery small and inconsistent revenue with swingy gross and net results indicates the company lacks stable operating income streams; headline profits appear driven by non‑operating items, reducing earnings quality and leaving long-term sustainability dependent on transactional events.
Extremely Limited Internal ResourcesAn operational headcount of two implies minimal in‑house development capacity, increasing reliance on CROs, partners and external expertise; this constrains speed and control over multiple programs and raises execution risk for advancing clinical candidates reliably.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was CHF0.03 and its highest was CHF0.09 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF5.40M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Jun 15, 2026 which is in 5 days.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in CH:ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Options Prices
Currently, No data available
---